Expression of cyclo-oxygenase-2 and downstream enzymes in diabetic fibrovascular epiretinal membranes

British Journal of Ophthalmology

Volumn 92, Issue 11, 2008, Pages 1534-1539

  Abu El Asrar, A M ^a,c   Missotten, L ^b   Geboes, K ^b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c KING ABDUL AZIZ UNIVERSITY HOSPITAL   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; PROSTAGLANDIN E SYNTHASE 1; THROMBOXANE SYNTHASE; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE ACTIVITY; ENDOTHELIUM CELL; EPIRETINAL MEMBRANE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STROMA CELL; VASCULARIZATION;

CYCLOOXYGENASE 2; DIABETIC RETINOPATHY; EPIRETINAL MEMBRANE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTRAMOLECULAR OXIDOREDUCTASES; MALE; NF-KAPPA B; RETINAL NEOVASCULARIZATION; STROMAL CELLS; THROMBOXANE-A SYNTHASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 55449103992     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2008.142182     Document Type: Article

References (25)

1. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 2001;280:1358-66C.
2. Miller JW, Adamis AP, Aiello LP. Vascular endothelial growth factor in ocular neovascularization and proliferative retinopathy. Diabetes Metab Rev 1997;13:37-50.
3. Joussen AM, Poulaki V, Le ML, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004;18:1450-2.
4. Hla T, Ristimaki A, Appleby S, et al. Cyclooxygenase gene expression in inflammation and angiogenesis. Ann NY Acad Sci 1993;696:197-204.
5. Kuwano T, Nakao S, Yamamoto H, et al. Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis. FASEB J 2004;18:300-10.
6. 2 regulation of endothelial cell migration, angiogenesis, and tumor metastasis. Biochem Biophys Res Commun 2000;267:245-51.
7. Murakami M, Kudo I. Prostaglandin E synthase: a novel drug target for inflammation and cancer. Curr Pharm Des 2006;12:943-54.
8. Shibata A, Nagaya T, Imai T, et al. Inhibition of NF-KappaB activity decreases the VEGF mRNA expression in MDA-MB-231 breast cancer cells. Breast Cancer Res Treat 2002;73:237-43.
9. κB p65 transcription factor in human vascular endothelial cells. J Biol Chem 1997;272:601-8.
10. κB. Diabetes 2001;50:2792-808.
11. Ogata N, Nishikawa M, Nishimura T, et al. Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. Am J Ophthalmol 2002;134:348-53.
12. Cook-Johnson RJ, Demasi M, Cleland LG, et al. Endothelial cell COX-2 expression and activity in hypoxia. Biochem Biophysic Acta 2006;1761:1443-9.
13. Bagi Z, Erdei N, Papp Z, et al. Up-regulation of vascular cyclooxygenase-2 in diabetes mellitus. Pharmacol Rep 2006; 58(Suppl):52-6S.
14. Sheu ML, Ho FM, Yang RS, et al. High glucose induces human endothelial cell apoptosis through a phosphoinositide 3-kinase-regulated cyclooxygenase-2 pathway. Arterioscler Thromb Vasc Biol 2005;25:539-45.
15. Nakao S, Kuwano T, Tsutsumi-Miyahara C, et al. Infiltration of COX-2 expressing macrophages is a prerequisite for IL-beta-induced neovascularization and tumor growth. J Clin Invest 2005;115:2979- 91.
16. Ikeda-Matsuo Y, Ota A, Fukada T, et al. Microsomal prostaglandin E-synthase 1 is a critical factor of stroke-reperfusion injury. Proc Natl Acad Sci USA 2006;103:11790-5.
17. Churchman A, Baydoun AR, Huffman R. Inhibition of angiogenic tubule formation and induction of apoptosis in human endothelial cells by the selective cyclooxygenase-2 inhibitor 5-bromo-2-(4-fluorophenyl|-3- (methylsufonyl) thiophene (DuP-697). Eur J Pharmacol 2007;573:176- 83.
18. Huang SP, Wu MS, Shun CT, et al. Cyclooxygenase-2 increases hypoxia-inducible factor-1 and vascular endothelial growth factor to promote angiogenesis in gastric carcinoma. J Biomed Sci 2005;12:229-41.
19. Gallo O, Franchi A, Magnelli L, et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 2001;3:53-61.
20. Abe A, Fukui H, Fujii S, et al. Involvement of cyclooxygenase-2 and vascular endothelial growth factor in vascularization and lymph node metastasis of colorectal cancers with submucosal invasion. J Gastroenterol Hepatol 2007;22:1071-7.
21. κB parallels COX-2 expression in oral precancer and cancer: Association with smokeless tobacco. Int J Cancer 2007;120:2545-56.
22. Xin B, Yokoyama Y, Shigeto T, et al. Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferators-activated receptor gamma ligand, on the growth of human ovarian cancers. Cancer 2007;110:791-800.
23. 2 and vascular endothelial growth factor (VEGF) in angiogenesis in human vascular endothelial cells. Vasc Pharmacol 2006;44:411-16.
24. Abu El-Asrar AM, Missotten L, Geboes K. Expression of hypoxia-inducible factor-1 alpha and the protein products of its target genes in diabetic fibrovascular epiretinal membranes. Br J Ophthalmol 2007;91:822-6.
25. Wilkinson-Berka JL, Alousis NS, Kelly DJ, et al. COX-2 inhibition and retinal angiogenesis in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2003;44:974-9.